Excalibur Medicines

Excalibur Medicines is a clinical-stage biotechnology company based in the United Kingdom, established by Professor Sir Chris Evans. The company is a subsidiary of Excalibur Healthcare Services and focuses on the development of treatments for severe inflammatory conditions and infectious diseases. Its primary asset is EXC154 (azeliragon), an orally administered small molecule that acts as an antagonist to the Receptor for Advanced Glycation End-products (RAGE). Excalibur Medicines has focused on evaluating EXC154 for the treatment of hospitalized COVID-19 patients to mitigate the inflammatory response and improve clinical outcomes. The company leverages a network of international scientific experts and clinical trial infrastructure to advance its therapeutic candidates.